Crohn's disease and ulcerative colitis are examples of inflammatory bowel disease, which is a group of diseases that cause persistent inflammation of the digestive tract. These illnesses are now major public health concerns. With the development of targeted biologic therapies, the improvement of older therapies like immunomodulators and 5-aminosalicylic acid, and a deeper understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD, medical therapy for IBD has advanced dramatically in the last decade. Inflammatory bowel disease treatment aims to achieve and sustain remission. The standard practice in medicine nowadays is to start with less intense treatments and work our way up to more intense ones if those fail or if the patient reports that their illness is particularly aggressive. For this reason, multi-unit carriers are preferable over single-unit ones. Pectin, among other biopolymers, stands out as a promising option for building colon-specific carriers that are activated by microbes. In this article, we will discuss the current methods of managing inflammatory bowel illness with multi particle medication delivery.

Mesalamine, Multi-particulate, Management, and Inflammatory Bowel Disease